Molecular pathogenesis of thyroid cancer

被引:69
作者
Segev, DL
Umbricht, C
Zeiger, MA
机构
[1] Johns Hopkins Med Inst, Dept Surg, Div Endocrine & Oncol Surg, Baltimore, MD 21287 USA
[2] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA
[3] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
[4] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
来源
SURGICAL ONCOLOGY-OXFORD | 2003年 / 12卷 / 02期
关键词
thyroid cancer; oncogenes; tumor suppressor genes; growth hormones; telomerase;
D O I
10.1016/S0960-7404(03)00037-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A number of molecular abnormalities have been described in association with the progression from normal thyroid tissue to benign adenomas to well-differentiated and finally anaplastic epithelial thyroid cancer. These include upregulation of proliferative factors, such as growth hormones and oncogenes, downregulation of apoptotic and cell-cycle inhibitory factors, such as tumor suppressors, disruption of normal cell-to-cell interactions, and cellular immortalization. The progression model for thyroid carcinoma has not been proven, but evidence suggests that an evolutionary molecular process is involved, especially in the development of follicular thyroid cancers for which there are distinct intermediate phenotypes. We present a comprehensive evaluation of factors involved in thyroid tumorigenesis and attempt to describe preliminary attributes of a progression model. The organization of this model should also provide a template for the incorporation of new information as it is derived from large-scale genomic studies. (C) 2003 Published by Elsevier Ltd.
引用
收藏
页码:69 / 90
页数:22
相关论文
共 306 条
[1]   GROWTH-FACTORS AND CANCER [J].
AARONSON, SA .
SCIENCE, 1991, 254 (5035) :1146-1153
[2]   EXPRESSION OF ONCOGENES IN THYROID-TUMORS - COEXPRESSION OF C-ERBB2/NEU AND C-ERBB [J].
AASLAND, R ;
LILLEHAUG, JR ;
MALE, R ;
JOSENDAL, O ;
VARHAUG, JE ;
KLEPPE, K .
BRITISH JOURNAL OF CANCER, 1988, 57 (04) :358-363
[3]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[4]  
Akahani S, 1997, CANCER RES, V57, P5272
[5]   ONCOGENIC ACTIVITY OF THE C-MYC PROTEIN REQUIRES DIMERIZATION WITH MAX [J].
AMATI, B ;
BROOKS, MW ;
LEVY, N ;
LITTLEWOOD, TD ;
EVAN, GI ;
LAND, H .
CELL, 1993, 72 (02) :233-245
[6]   TRANSCRIPTIONAL ACTIVATION BY THE HUMAN C-MYC ONCOPROTEIN IN YEAST REQUIRES INTERACTION WITH MAX [J].
AMATI, B ;
DALTON, S ;
BROOKS, MW ;
LITTLEWOOD, TD ;
EVAN, GI ;
LAND, H .
NATURE, 1992, 359 (6394) :423-426
[7]   DIPEPTIDYL AMINOPEPTIDASE-IV STAINING OF CYTOLOGIC PREPARATIONS TO DISTINGUISH BENIGN FROM MALIGNANT THYROID-DISEASES [J].
ARATAKE, Y ;
KOTANI, T ;
TAMURA, K ;
ARAKI, Y ;
KURIBAYASHI, T ;
KONOE, K ;
OHTAKI, S .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1991, 96 (03) :306-310
[8]   Iodide symporter gene expression in human thyroid tumors [J].
Arturi, F ;
Russo, D ;
Schlumberger, M ;
du Villard, JA ;
Caillou, B ;
Vigneri, P ;
Wicker, R ;
Chiefari, E ;
Suarez, HG ;
Filetti, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07) :2493-2496
[9]   Expression of cytokines in the thyroid: Thyrocytes as potential cytokine producers [J].
Aust, G ;
Scherbaum, WA .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1996, 104 :64-67
[10]  
BACCHETTI S, 1995, INT J ONCOL, V7, P423